Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Plus Therapeutics Inc
PSTV | US
0.30
USD0.01
2.25%
PSTV | US
About Plus Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
09/03/2026
Close
0.30
Open
0.28
High
0.30
Low
0.28
Plus Therapeutics Inc. a clinical-stage pharmaceutical company focuses on the development manufacture and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186Re obisbemeda a patented radiotherapy that targets central nervous system cancers including recurrent glioblastoma leptomeningeal metastases and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics Inc. and changed its name to Plus Therapeutics Inc. in July 2019. Plus Therapeutics Inc. was founded in 1996 and is headquartered in Austin Texas.
View LessPSTV | US
Risk
70.3
Sharpe
-0.35
Luna's Score
40/100
Recommendation
Sell
Luna says (PSTV | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
What's not Working
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
77.2%1 month
70.3%3 months
113.1%6 months
129.0%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
3.76
Debt to equity
-0.45
Debt to assets
0.31
Ent. to EBITDA
-0.30
Ent. to rev.
18.19
PEG
-
Other Fundamentals
EBITDA
-13.47M
MarketCap
1.74M
MarketCap(USD)
1.74M
Div. yield
-
Op. margin
-289.05
Erngs. growth
-
Rev. growth
-31.00
Ret. on equity
-522.50
Short ratio
1.20
Short perc.
1.65
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.09
Range1M
0.11
Range3M
0.55
Volumes: Market Activity
Rel. volume
0.72
Price X volume
1.08M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.30 | 0.53 | Cheaper |
| Ent. to Revenue | 18.19 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.76 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 113.05 | 72.80 | Riskier |
| Debt to Equity | -0.45 | -1.23 | Expensive |
| Debt to Assets | 0.31 | 0.25 | Expensive |
| Market Cap | 1.74M | 3.66B | Emerging |
